SAN DIEGO, Feb. 15, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) (“MabVax” or the “Company”), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced…